New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Austria ,Vienna ,Wien ,Bristol Myers Squibbmedia ,Jonathan Sadeh ,Hans Peter Hartung ,Bristol Myers Squibb ,Patrick Vermersch ,Bruce Cree ,John Deluca ,Instagram ,Linkedin ,Twitter ,Ucsf Ms Center ,European Academy Of Neurology ,European Commission ,Drug Administration ,Exchange Commission ,Youtube ,Facebook ,University Of California San Francisco ,Fibrosis Development ,Weill Institute For Neurosciences ,Myers Squibb ,European Academy ,Clinical Neurology ,California San Francisco ,Weill Institute ,Bristol Myers ,Myers Squibb Sponsored ,Ralf Gold ,Multifocal Leukoencephalopathy ,Atrioventricular Conduction Delays ,Blood Pressure ,Reversible Encephalopathy Syndrome ,Immune Modulating Drugs ,Disability After Stopping ,Common Adverse Reactions ,Prescribing Information ,Pioneering Paths Forward ,Transform Patient ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,Myers Squibbmedia Inquiries ,Business Wire ,Covid 19 ,Politics ,Health ,Multiple Sclerosis ,Europe ,Congress ,Business ,